Abstract
Vemurafenib has recently been approved for treating advanced melanoma. Targeting the V600 mutation in BRAF , this agent improves progression-free and overall survival of melanoma patients with tumors carrying that mutation. Keratoacanthomas and squamous cell carcinomas (SCCs) are well-known adverse effects of vemurafenib. Two study groups recently characterized other adverse cutaneous reactions in vemurafenib recipients. Gelot and colleagues describe vemurafenib-associated photosensitivity in 10 of 18 previously untreated …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
